Immune Spatial Features of Guselkumab Cutaneous Response
Recruiting
Phase 4
Interventional Study
Psoriasis of Scalp
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 10 (estimated)
- Sponsor
- University of California, San Francisco · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12
Exclusion Criteria:
1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active s…